ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. The company specialises in high quality medicines for the treatment of important diseases in the livestock sector. ECO Animal Health are dedicated to the research, development and marketing of strong brands, differentiated generics and innovative new solutions.

11 Mar 2026

ECOVAXXIN® MG receives US safety validation

Following the recent announcement of plans for commercialisation of ECOVAXXIN^® MS, ECO Animal Health announces that the United States Department of Agriculture (USDA) has delivered a favourable safety assessment of ECOVAXXIN^® MG, the Company’s live poultry vaccine targeting Mycoplasma gallisepticum.

The USDA review and acceptance of ECOVAXXIN^®MG safety data represents an important step towards securing marketing authorisation for the vaccine in the United States.

EAH has estimated that ECOVAXXIN^® MG has the potential to contribute peak revenue of c.£10.0m by 2036 as part of a portfolio of new products under development of which ECOVAXXIN^® MG stands in the ‘late stage’, i.e. early contributor segment. The USDA safety approval acceptance adds further momentum to the path toward commercialisation for the vanguard of nine major products under development.

Our fair value remains at 153p/share.

Download as a PDF file

Return to ECO Animal Health

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE

Website design & development by Breckenridge